shengnuo biotechnology: Subsidiary Octreotide Acetate API was certified by the European Medicines Agency

shengnuo biotechnology: Subsidiary Octreotide Acetate API was certified by the European Medicines Agency

shengnuo biotechnologylogical announced that Chengdu shengnuo biotechnology-Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has recently obtained the European Pharmacopoeia Applicability Certificate for Octreotide Acetate API (referred to as “CEP Certificate”) issued by the European Medicines Agency. Octreotide acetate preparation products are mainly used in For emergency treatment of esophageal-gastric varices bleeding caused by liver cirrhosis, combined with special treatment (such as endoscopic sclerotherapy); prevention of postoperative complications of pancreas; relief of symptoms and signs related to gastroenteroendocrine tumors, etc.